Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement that the Group has obtained drug production registration approval from the China National Drug Administration (CNDA) for levofloxacin eye drops (0.488% (5ml: 24.4 mg)), which is a Class 4 chemical and is deemed to have passed the consistency evaluation. Levofloxacin eye drops are mainly used to treat blepharitis, blepharitis, dacryocystitis, conjunctivitis, blepharitis, keratitis, and sterile therapy during the perioperative period of ophthalmology. This approval has made the Group increasingly rich in the variety of ophthalmic preparations.

Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement that the Group has obtained drug production registration approval from the China National Drug Administration (CNDA) for levofloxacin eye drops (0.488% (5ml: 24.4 mg)), which is a Class 4 chemical and is deemed to have passed the consistency evaluation. Levofloxacin eye drops are mainly used to treat blepharitis, blepharitis, dacryocystitis, conjunctivitis, blepharitis, keratitis, and sterile therapy during the perioperative period of ophthalmology. This approval has made the Group increasingly rich in the variety of ophthalmic preparations.